ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma
Posted: Friday, January 3, 2020
A phase I dose-finding study—presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida (Abstract 143)—indicated that CC-93269, a B-cell maturation antigen (BCMA) tumor necrosis factor receptor, appears to have a manageable safety profile and may prove to be effective among patients with relapsed or refractory multiple myeloma. Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, and colleagues noted that although several patients developed cytokine-release syndrome, CC-93269 was associated with high response rates.
The research team treated 19 patients with relapsed or refractory multiple myeloma with CC-93269. Patients were eligible if they had received at least three prior regimens without BCMA-directed therapy.
The doses of CC-93269 ranged from 0.15 to 10 mg, with a median duration of treatment of 14.6 weeks. Overall, 15 patients (78.9%) reported treatment-emergent adverse events, including neutropenia (52.6%), anemia (42.1%), infections (26.3%), and thrombocytopenia (21.1%). The researchers observed cytokine-release syndrome in 17 patients (89.5%), which occurred most frequently with the first or second dose. Dexamethasone and tocilizumab were used to manage cytokine-release syndrome.
Although cytokine-release syndrome developed in many patients, the research team also reported relatively high response rates. Of the 12 patients treated with at least 6 mg of CC-93269 in cycle 1, 10 patients (83.3%) achieved a partial response or better. The investigators reported a median time to response of 4.2 weeks.
“The study continues to enroll [patients] in the dose-escalation phase,” the authors noted.
Disclosure: For full disclosures of study authors, visit, ash.confex.com.
